Active Research Studies: Lymphoma

Comprehensive Cancer Centers is currently running the following Phase II and Phase III clinical research studies for lymphoma:

An International, Phase 2, Open-Label, Randomized Study of BGB-3111 Combined with Obinutuzumab Compared With Obinutuzumab Monotherapy in Relapsed/Refractory Follicular Lymphoma
Study#: i2484 Phase II
Contact Us: For information about this clinical study, Email Us, or use our form field.

A Randomized Phase 3 Study to Evaluate the Efficacy and Safety of Enzastaurin Plus R-CHOP Versus R-CHOP in Treatment-Naïve Subjects with High-Risk Diffuse Large B-Cell Lymphoma Who Possess the Novel Genomic BiomarkerDGM1
Study#: i2571 Phase III
Contact Us: For information about this clinical study, Email Us, or use our form field.

A Phase 3, Randomized Study of Zanubrutinib (BGB-3111) Compared with Ibrutinib in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma **22 SLOTS AVAILABLE**
Study#: i2618 Phase III
Contact Us: For information about this clinical study, Email Us, or use our form field.

A Phase 3 Randomized, Open-Label, Multicenter Study Comparing Zanubrutinib (BGB-3111) plus Rituximab Versus Bendamustine plus Rituximab in Patients with Previously Untreated Mantle Cell Lymphoma Who Are Ineligible for Stem Cell Transplantation
Study#: i2680 Phase III
Contact Us: For information about this clinical study, Email Us, or use our form field.

A phase 2 open-label study of brentuximab vedotin in front-line therapy of Hodgkin lymphoma (HL) and CD30-expressing peripheral T-cell lymphoma (PTCL) in adults age 60 and above
Study#: 11282 Phase II
Contact Us: For information about this clinical study, Email Us, or use our form field.

A phase 2, multicenter, single-arm study of retreatment with brentuximab vedotin in subjects with relapsed or refractory classic Hodgkin lymphoma (cHL) or CD30-expressing peripheral T cell lymphoma (PTCL)
Study#: i2698 Phase II
Contact Us: For information about this clinical study, Email Us, or use our form field.

A Single-Arm, Expanded Access Study of Zanubrutinib (BGB-3111) in Patients with B-cell Malignancies
Study#: i2702
Contact Us: For information about this clinical study, Email Us, or use our form field.

A Phase 2, Randomized, Open-label, 2-Arm Study Comparing 2 Intermittent Dosing Schedules of Duvelisib in Subjects with Indolent Non-Hodgkin Lymphoma (iNHL)
Study#: i2713
Contact Us: For information about this clinical study, Email Us, or use our form field.

A Phase 2, Multicenter, Single-arm Study of Zanubrutinib (BGB-3111) in Patients with Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Intolerant of Prior Treatment with Ibrutinib
Study#: 18263
Contact Us: For information about this clinical study, Email Us, or use our form field.

SGN35-027: Multiple Part Clinical Trial of Brentuximab Vedotin in Classical Hodgkin Lymphoma Subjects
Study#: 18013
Contact Us: For information about this clinical study, Email Us, or use our form field.